Department of Surgery, The Methodist Hospital, Houston, Texas 77030, USA.
Drugs. 2010 Apr 16;70(6):691-732. doi: 10.2165/11315940-000000000-00000.
The more than 25 years of clinical experience with rabbit antithymocyte globulin (rATG), specifically Thymoglobulin, has transformed immunosuppression in solid organ transplantation and haematology. The utility of rATG has evolved from the treatment of allograft rejection and graft-versus-host disease to the prevention of various complications that limit the success of solid organ and stem cell transplantation. Today, rATG is being successfully incorporated into novel therapeutic regimens that seek to reduce overall toxicity and improve long-term outcomes. Clinical trials have demonstrated the efficacy and safety of rATG in recipients of various types of solid organ allografts, recipients of allogeneic stem cell transplants who are conditioned with both conventional and nonconventional regimens, and patients with aplastic anaemia. Over time, clinicians have learnt how to better balance the benefits and risks associated with rATG. Advances in the understanding of the multifaceted mechanism of action will guide research into new therapeutic areas and future applications.
兔抗胸腺细胞球蛋白（rATG），尤其是 Thymoglobulin，在临床应用已超过 25 年，它改变了实体器官移植和血液学中的免疫抑制治疗。rATG 的应用已从治疗移植物排斥反应和移植物抗宿主病发展到预防各种限制实体器官和干细胞移植成功的并发症。如今，rATG 成功地纳入了旨在降低整体毒性和改善长期结果的新型治疗方案中。临床试验证明了 rATG 在各种类型实体器官同种异体移植物受者、接受传统和非传统方案预处理的异基因干细胞移植受者以及再生障碍性贫血患者中的疗效和安全性。随着时间的推移，临床医生已经学会了如何更好地平衡 rATG 相关的获益与风险。对其多效作用机制的深入理解将指导新的治疗领域和未来应用的研究。
